https://m2.mtmt.hu/ hun 2026-09-23 10:32 JournalArticle 32666145 VALIDATED true Tamás Radovits and János Szebeni contributed equally to the article. 0 false 2026-09-03T08:28:21.338+0000 2026-09-03T08:26:50.466+0000 2022-02-11T08:56:52.791+0000 true 10069606 Pintér Ibolya Katalin /api/admin/10069606 Admin Pintér Ibolya Katalin (SE_AOK_TranszlációsMedInt_Admin5_PI, admin) true 2026-09-03T09:25:58.876+0000 2026-09-03T09:25:58.876+0000 2024-01-04T07:36:45.050+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Dézsi, László true true /api/journal/10071822 REVIEWED GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 true false 10071822 false 10071822 true 2509-2715 2509-2723 Journal FOREIGN 44 2 597 618 597 22 2022 A tiny fraction of people immunized with lipid nanoparticle (LNP)-enclosed mRNA (LNP-mRNA) vaccines develop allergic symptoms following their first or subsequent vaccinations, including anaphylaxis. These reactions resemble complement (C) activation-related pseudoallergy (CARPA) to i.v. administered liposomes, for which pigs provide a naturally oversensitive model. Using this model, we injected i.v. the human vaccination dose (HVD) of BNT162b2 (Comirnaty, CMT) or its 2-fold (2x) or 5-fold (5x) amounts and measured the hemodynamic changes and other parameters of CARPA. We observed in 6 of 14 pigs transient pulmonary hypertension along with thromboxane A2 release into the blood and other hemodynamic and blood cell changes, including hypertension, granulocytosis, lymphopenia, and thrombocytopenia. One pig injected with 5x CMT developed an anaphylactic shock requiring resuscitation, while a repeat dose failed to induce the reaction, implying tachyphylaxis. These typical CARPA symptoms could not be linked to animal age, sex, prior immune stimulation with zymosan, immunization of animals with Comirnaty i.v., or i.m. 2 weeks before the vaccine challenge, and anti-PEG IgM levels in Comirnaty-immunized pigs. Nevertheless, IgM binding to the whole vaccine, used as antigen in an ELISA, was significantly higher in reactive animals compared to non-reactive ones. Incubation of Comirnaty with pig serum in vitro showed significant elevations of C3a anaphylatoxin and sC5b-9, the C-terminal complex. These data raise the possibility that C activation plays a causal or contributing role in the rare HSRs to Comirnaty and other vaccines with similar side effects. Further studies are needed to uncover the factors controlling these vaccine reactions in pigs and to understand their translational value to humans. Funding 2010441 /api/funding/2010441 (Open access funding of Semmelweis University) false true Funding 2010442 /api/funding/2010442 European Union Horizon 2020 projects(825828) false true Funding 2010443 /api/funding/2010443 European Union Horizon 2020 projects(952520) false true Funding 2010444 /api/funding/2010444 (2020-1.1.6-JOVO-2021-00013) false true true true 2022 true true true false true false GREEN 2026-09-03 true https://doi.org/10.1007/s11357-021-00495-y 51 0 47 35 13 47 46 42 37 45 45 33 33 37 14 0 51 37 47 35 0 20 20 Folyóiratcikk Journal Article 24 47 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 1 Egyéb Miscellaneous 29 3 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 6 4 6 4 2023 0 12 8 12 8 2024 0 16 12 16 12 2025 0 11 7 11 7 2026 0 6 6 6 6 D1 false 10005165,10075617 false false false 2022-02-20T14:12:01.078+0000 Elméleti Egészségtudományok Intézete (ME / ETK); Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Sportorvostan Tanszék (SE / AOK / K); Transzlációs Medicina Intézet (SE / AOK / I); Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K) 11 67 5 14 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 100555569 /api/authorship/100555569 Dézsi, László [Dézsi, László (Elméleti orvostud...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Transzlációs Medicina Intézet (SE / AOK / I) 1 0.071 true false false Author 10005165 /api/author/10005165 Dézsi László (Elméleti orvostudományok) Dézsi László true 10005165 true Dézsi László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555570 /api/authorship/100555570 Mészáros, Tamás [Mészáros, Tamás (nanomedicina), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Transzlációs Medicina Intézet (SE / AOK / I) 2 0.071 false false false Author 10064003 /api/author/10064003 Mészáros Tamás (nanomedicina) Mészáros Tamás true 10064003 true Mészáros Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555571 /api/authorship/100555571 Kozma, Gergely Tibor [Kozma, Gergely Tibor (Immunológia, Mole...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Transzlációs Medicina Intézet (SE / AOK / I) 3 0.071 false false false Author 10024742 /api/author/10024742 Kozma Gergely Tibor (Immunológia, Molekuláris biológia) Kozma Gergely Tibor true 10024742 true Kozma Gergely Tibor true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555572 /api/authorship/100555572 H-Velkei, Mária 4 0.071428575 false false false H-Velkei Mária true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555573 /api/authorship/100555573 Oláh, Csaba Zs. [Oláh, Csaba Zsolt (idegsebészet), szerző] 5 0.071428575 false false false Author 10075617 /api/author/10075617 Oláh Csaba Zsolt (idegsebészet) Oláh Csaba Zsolt true true Oláh Csaba Zs. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555574 /api/authorship/100555574 Szabó, Miklós [Szabó, Miklós (tüdőgyógyászat, k...), szerző] 6 0.071428575 false false false Author 10092665 /api/author/10092665 Szabó Miklós (tüdőgyógyászat, klinikai onkológia) Szabó Miklós true true Szabó Miklós true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555575 /api/authorship/100555575 Patkó, Zsófia [Patkó, Zsófia Panna (farmakokinetika, ...), szerző] 7 0.071428575 false false false Author 10032791 /api/author/10032791 Patkó Zsófia Panna (farmakokinetika, nukleáris medicina, radiológia) Patkó Zsófia Panna DUPLUM true 10032791 true Patkó Zsófia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555576 /api/authorship/100555576 Fülöp, Tamás [Fülöp, Tamás (Liposzomális nano...), szerző] Transzlációs Medicina Intézet (SE / AOK / I) 8 0.071 false false false Author 10053120 /api/author/10053120 Fülöp Tamás (Liposzomális nanomedicina vizsgálatok) Fülöp Tamás true 10053120 true Fülöp Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555577 /api/authorship/100555577 Hennies, Mark 9 0.071428575 false false false Hennies Mark true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555578 /api/authorship/100555578 Szebeni, Miklós 10 0.071428575 false false false Szebeni Miklós true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555579 /api/authorship/100555579 Barta, Bálint András [Barta, Bálint András (Experimentális ka...), szerző] Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K) 11 0.071 false false false Author 10072454 /api/author/10072454 Barta Bálint András (Experimentális kardiológia, Proteomika) Barta Bálint András true true Barta Bálint András true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555580 /api/authorship/100555580 Merkely, Béla [Merkely, Béla Péter (Kardiológia), szerző] Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K); Sportorvostan Tanszék (SE / AOK / K) 12 0.071 false false false Author 10002691 /api/author/10002691 Merkely Béla Péter (Kardiológia) Merkely Béla Péter true 10002691 true Merkely Béla true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555581 /api/authorship/100555581 Radovits, Tamás** [Radovits, Tamás (kardiológia, érgy...), szerző] Városmajori Szív- és Érgyógyászati Klinika (SE / AOK / K) 13 0.071 false true false Author 10013969 /api/author/10013969 Radovits Tamás (kardiológia, érgyógyászat) Radovits Tamás true 10013969 true Radovits Tamás true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100555582 /api/authorship/100555582 Szebeni, János ✉ [Szebeni, János (Klinikai orvostud...), szerző] Nanomedicina Kutató és Oktató Központ (SE / AOK / I / KKI); Elméleti Egészségtudományok Intézete (ME / ETK); Transzlációs Medicina Intézet (SE / AOK / I) 14 0.071 false true true Author 10003266 /api/author/10003266 Szebeni János (Klinikai orvostudomány, immunológia, nanomedicina) Szebeni János true 10003266 true Szebeni János true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 20669930 /api/publicationidentifier/20669930 DOI: 10.1007/s11357-021-00495-y PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GREEN true IDENTICAL 10.1007/s11357-021-00495-y https://doi.org/10.1007/s11357-021-00495-y false true PublicationIdentifier 20757377 /api/publicationidentifier/20757377 WoS: 000753709600001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000753709600001 https://www.webofscience.com/wos/woscc/full-record/000753709600001 true true PublicationIdentifier 20702173 /api/publicationidentifier/20702173 Scopus: 85124573206 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85124573206 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124573206 false true PublicationIdentifier 20664648 /api/publicationidentifier/20664648 PubMed: 35146583 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 35146583 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35146583&dopt=Abstract false true SjrRating 11312161 /api/sjrrating/11312161 sjr:D1 (2022) Scopus - Complementary and Alternative Medicine GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 1 0.0 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2707 /api/classificationexternal/2707 Scopus - Complementary and Alternative Medicine true 2707 true D1 DIRECT true true Reference 27911694 /api/reference/27911694 1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15., DOI: 10.1056/NEJMoa2034577 1 10.1056/NEJMoa2034577 false true Reference 27911695 /api/reference/27911695 2. CDC. Interim considerations: preparing for the potential management of anaphylaxis at COVID-19 vaccination sites summary. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html. Accessed 19 Dec 2021 2 false true Reference 27911696 /api/reference/27911696 3. Garvey LH, Nasser S. Anaphylaxis to the first COVID-19 vaccine: is polyethylene glycol (PEG) the culprit? Br J Anaesth. 2021;126(3):e106ee132, DOI: 10.1016/j.bja.2020.12.020 3 10.1016/j.bja.2020.12.020 false true Reference 27911697 /api/reference/27911697 4. Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA, Jr., Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy. 2021;76(9):2916–2920., DOI: 10.1111/all.14958 4 10.1111/all.14958 false true Reference 27911698 /api/reference/27911698 5. Hashimoto T, Ozaki A, Bhandari D, Sawano T, Sah R, Tanimoto T. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese health care workers; a secondary analysis of initial post-approval safety data. J Travel Med. 2021., DOI: 10.1093/jtm/taab090 5 10.1093/jtm/taab090 false true Reference 27911699 /api/reference/27911699 6. Sellaturay P, Nasser S, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. Clin Exp Allergy. 2021;51(6):861–3., DOI: 10.1111/cea.13874 6 10.1111/cea.13874 false true Reference 27911700 /api/reference/27911700 7. Risma KA, Edwards KM, Hummell DS, Little FF, Norton AE, Stallings A, Wood RA, Milner JD. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021., DOI: 10.1016/j.jaci.2021.04.002 7 10.1016/j.jaci.2021.04.002 false true Reference 27911701 /api/reference/27911701 8. Shimabukuro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021., DOI: 10.1001/jama.2021.0600 8 10.1001/jama.2021.0600 false true Reference 27911702 /api/reference/27911702 9. Team CC-R, Food, Drug A. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(4):125–9., DOI: 10.15585/mmwr.mm7004e1 9 10.15585/mmwr.mm7004e1 false true Reference 27911703 /api/reference/27911703 10. Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, Betts B, Buzzanco AS, Gonzalez J, Chinthrajah RS, Do E, Chang I, Dunham D, Lee G, O’Hara R, Park H, Shamji MH, Schilling L, Sindher SB, Sisodiya D, Smith E, Tsai M, Galli SJ, Akdis C, Nadeau KC. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system. JAMA Netw Open. 2021;4(9):e2125524., DOI: 10.1001/jamanetworkopen.2021.25524 10 10.1001/jamanetworkopen.2021.25524 false true Reference 27911704 /api/reference/27911704 11. Gringeri M, Mosini G, Battini V, Cammarata G, Guarnieri G, Carnovale C, Clementi E, Radice S. Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility. Hum Vaccin Immunother. 2021;17(9):2969–71., DOI: 10.1080/21645515.2021.1917236 11 10.1080/21645515.2021.1917236 false true Reference 27911705 /api/reference/27911705 12. Mathioudakis AG, Ghrew M, Ustianowski A, Ahmad S, Borrow R, Papavasileiou LP, Petrakis D, Bakerly ND. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: a vaccine recipient survey. Life. 2021;11(3):249. https://doi.org/10.3390/life11030249, DOI: 10.3390/life11030249 12 10.3390/life11030249 false true Reference 27911706 /api/reference/27911706 13. Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61:163–73., DOI: 10.1016/j.molimm.2014.06.038 13 10.1016/j.molimm.2014.06.038 false true Reference 27911707 /api/reference/27911707 14. Szebeni J, Storm G, Ljubimova JY, Mariana Castells M, Phillips EJ, Turjeman K, Barenholz Y, Marina A. Dobrovolskaia MA, Crommelin DJA. Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-coV2 vaccines. Nat Nanotechnol. 2022. https://doi.org/10.1038/s41565-022-01071-x, DOI: 10.1038/s41565-022-01071-x 14 10.1038/s41565-022-01071-x false true Reference 27911708 /api/reference/27911708 15. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, Stahl GL, Bunger R, Alving CR. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation. 1999;99(17):2302–9., DOI: 10.1161/01.CIR.99.17.2302 15 10.1161/01.CIR.99.17.2302 false true Reference 27911709 /api/reference/27911709 16. Szebeni J, Bedocs P, Csukas D, Rosivall L, Bunger R, Urbanics R. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines. Adv Drug Deliv Rev. 2012;64(15):1706–16., DOI: 10.1016/j.addr.2012.07.005 16 10.1016/j.addr.2012.07.005 false true Reference 27911710 /api/reference/27911710 17. Urbanics R, Szebeni J. Lessons learned from the porcine CARPA model: constant and variable responses to different nanomedicines and administration protocols. Eur J Nanomedicine. 2015;7:219–31., DOI: 10.1515/ejnm-2015-0011 17 10.1515/ejnm-2015-0011 false true Reference 27911711 /api/reference/27911711 18. Szebeni J, Bawa R. Human clinical relevance of the porcine model of pseudoallergic infusion reactions. Biomedicines 2020;8(4):82. https://doi.org/10.3390/biomedicines8040082, DOI: 10.3390/biomedicines8040082 18 10.3390/biomedicines8040082 false true Reference 27911712 /api/reference/27911712 19. Prescribing information, COMIRNATY® (COVID-19 Vaccine, mRNA) suspension for injection, for intramuscular use. https://www.fda.gov/media/151707/download, 2021. Accessed 19 Dec 2021 19 false true Reference 27911713 /api/reference/27911713 20. Szebeni J, Baranyi L, Savay S, Bodo M, Milosevits J, Alving CR, Bunger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol. 2006;290(3):H1050–8., DOI: 10.1152/ajpheart.00622.2005 20 10.1152/ajpheart.00622.2005 false true Reference 27911714 /api/reference/27911714 21. Kozma GT, Meszaros T, Vashegyi I, Fulop T, Orfi E, Dezsi L, Rosivall L, Bavli Y, Urbanics R, Mollnes TE, Barenholz Y, Szebeni J. Pseudo-anaphylaxis to polyethylene glycol (PEG)-coated liposomes: roles of anti-PEG IgM and complement activation in a porcine model of human infusion reactions. ACS Nano. 2019;13(8):9315–24., DOI: 10.1021/acsnano.9b03942 21 10.1021/acsnano.9b03942 false true Reference 27911715 /api/reference/27911715 22. Jansen JH, Hogasen K, Mollnes TE. Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease). Am J Pathol. 1993;143(5):1356–65. 22 false true Reference 27911716 /api/reference/27911716 23. Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)–United States, 1991–2001. MMWR Surveill Summ. 2003;52(1):1–24. 23 false true Reference 27911717 /api/reference/27911717 24. Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the vaccine adverse event reporting system (VAERS). Vaccine. 2015;33(36):4398–405., DOI: 10.1016/j.vaccine.2015.07.035 24 10.1016/j.vaccine.2015.07.035 false true Reference 27911718 /api/reference/27911718 25. Vaccine adverse effect system. 2021. https://vaers.hhs.gov/. Accessed 19 Dec 2021 25 false true Reference 27911719 /api/reference/27911719 26. Austin T, Sun S, Lim YS, Nguyen D, Lea N, Tapuria A, Kalra D. An electronic healthcare record server implemented in PostgreSQL. J Healthc Eng. 2015;6(3):325–44., DOI: 10.1260/2040-2295.6.3.325 26 10.1260/2040-2295.6.3.325 false true Reference 27911720 /api/reference/27911720 27. Doxil. DOXIL® (doxorubicin hydrochloride liposome injection) 2021. 27 false true Reference 27911721 /api/reference/27911721 28. Szebeni J, Baranyi L, Savay S, Bodo M, Morse DS, Basta M, Stahl GL, Bunger R, Alving CR. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol Heart Circ Physiol. 2000;279(3):H1319–28., DOI: 10.1152/ajpheart.2000.279.3.H1319 28 10.1152/ajpheart.2000.279.3.H1319 false true Reference 27911722 /api/reference/27911722 29. ALZA Pharmaceuticals I. Doxil package insert. Mountain View, CA, USA. 2000. 29 false true Reference 27911723 /api/reference/27911723 30. Barenholz Y. Doxil(R)–the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117–34., DOI: 10.1016/j.jconrel.2012.03.020 30 10.1016/j.jconrel.2012.03.020 false true Reference 27911724 /api/reference/27911724 31. Fülöp TG, Metselaar JM, Gert Storm G, Szebeni J. The role of thromboxane A2 in complement activation-related pseudoallergy. Eur J Nanomed. 2017;9:59–67., DOI: 10.1515/ejnm-2016-0039 31 10.1515/ejnm-2016-0039 false true Reference 27911725 /api/reference/27911725 32. Szebeni J, Baranyi B, Savay S, Lutz LU, Jelezarova E, Bunger R, Alving CR. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J Liposome Res. 2000;10:347–61., DOI: 10.3109/08982100009031112 32 10.3109/08982100009031112 false true Reference 27911726 /api/reference/27911726 33. Neugut AI, Ghatak AT, Miller RL. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med. 2001;161(1):15–21., DOI: 10.1001/archinte.161.1.15 33 10.1001/archinte.161.1.15 false true Reference 27911727 /api/reference/27911727 34. Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med. 2021;384(7):643–9., DOI: 10.1056/NEJMra2035343 34 10.1056/NEJMra2035343 false true Reference 27911728 /api/reference/27911728 35. Rama TA, Moreira A, Castells M. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis. J Allergy Clin Immunol. 2021;147(3):877–8., DOI: 10.1016/j.jaci.2021.01.004 35 10.1016/j.jaci.2021.01.004 false true Reference 27911729 /api/reference/27911729 36. Herve C, Laupeze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019;4:39., DOI: 10.1038/s41541-019-0132-6 36 10.1038/s41541-019-0132-6 false true Reference 27911730 /api/reference/27911730 37. CDC. Clinical care consideraitons for COVID-2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/index.html. Accessed 19 Dec 2021 37 false true Reference 27911731 /api/reference/27911731 38. (NIAID) NIoAaID. COVID19 SARS vaccinations: systemic allergic reactions to SARS-CoV-2 vaccinations. (ID Number: DAIT COVID-19-004). https://www.niaid.nih.gov/clinical-trials/systemic-allergic-reactions-sars-cov-2-vaccination. Accessed 19 Dec 2021 38 false true Reference 27911732 /api/reference/27911732 39. Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB, Wickner P. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA. 2021;325(15):1562–5., DOI: 10.1001/jama.2021.3976 39 10.1001/jama.2021.3976 false true Reference 27911733 /api/reference/27911733 40. Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154–155:163–75., DOI: 10.1016/j.addr.2020.07.024 40 10.1016/j.addr.2020.07.024 false true Reference 27911734 /api/reference/27911734 41. Banerji A, Wickner PG, Saff R, Stone CA, Jr., Robinson LB, Long AA, Wolfson AR, Williams P, Khan DA, Phillips E, Blumenthal KG. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: current evidence and suggested approach. J Allergy Clin Immunol Pract. 2020., DOI: 10.1016/j.jaip.2020.12.047 41 10.1016/j.jaip.2020.12.047 false true Reference 27911735 /api/reference/27911735 42. Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA. Polyethylene glycol and polysorbate skin testing in the evaluation of Coronavirus disease 2019 vaccine reactions: early report. Ann Allergy Asthma Immunol. 2021;126(6):735–8., DOI: 10.1016/j.anai.2021.03.012 42 10.1016/j.anai.2021.03.012 false true Reference 27911736 /api/reference/27911736 43. Zhou ZH, Stone CA Jr, Jakubovic B, Phillips EJ, Sussman G, Park J, Hoang U, Kirshner SL, Levin R, Kozlowski S. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. J Allergy Clin Immunol Pract. 2021;9(4):1731-3.e3., DOI: 10.1016/j.jaip.2020.11.011 43 10.1016/j.jaip.2020.11.011 false true Reference 27911737 /api/reference/27911737 44. Krantz MS, Kwah JH, Stone CA, Jr., Phillips EJ, Ortega G, Banerji A, Blumenthal KG. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021., DOI: 10.1001/jamainternmed.2021.3779 44 10.1001/jamainternmed.2021.3779 false true Reference 27911738 /api/reference/27911738 45. Szebeni J, Bedocs P, Urbanics R, Bunger R, Rosivall L, Toth M, Barenholz Y. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Control Release. 2012;160(2):382–7., DOI: 10.1016/j.jconrel.2012.02.029 45 10.1016/j.jconrel.2012.02.029 false true Reference 27911739 /api/reference/27911739 46. Vrieze Jd. Suspicions grow that nanoparticles in Pfizer’s COVID-19 vaccine trigger rare allergic reactions. https://www.science.org/content/article/suspicions-grow-nanoparticles-pfizer-s-covid-19-vaccine-trigger-rare-allergic-reactions. Accessed 19 Dec 2021, DOI: 10.1126/science.abg2359 46 10.1126/science.abg2359 false true Reference 27911740 /api/reference/27911740 47. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carr Syst. 2001;18:567–606. 47 false true Reference 27911741 /api/reference/27911741 48. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology. 2005;216(2–3):106–21., DOI: 10.1016/j.tox.2005.07.023 48 10.1016/j.tox.2005.07.023 false true Reference 27911742 /api/reference/27911742 49. Moghimi SM. Allergic Reactions and anaphylaxis to LNP-based COVID-19 vaccines. Mol Ther J Am Soc Gene Ther. 2021;29(3):898–900., DOI: 10.1016/j.ymthe.2021.01.030 49 10.1016/j.ymthe.2021.01.030 false true Reference 27911743 /api/reference/27911743 50. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, Muggia FM. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol. 2003;14:1430–7., DOI: 10.1093/annonc/mdg374 50 10.1093/annonc/mdg374 false true Reference 27911744 /api/reference/27911744 51. Fernandez HN, Hugli TE. Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a. J Immunol. 1976;117:1688–94. 51 false true Reference 27911745 /api/reference/27911745 52. Gorski JP, Hugli TE, Muller-Eberhard HJ. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A. 1979;76(10):5299–302., DOI: 10.1073/pnas.76.10.5299 52 10.1073/pnas.76.10.5299 false true Reference 27911746 /api/reference/27911746 53. Gold MS, MacDonald NE, McMurtry CM, Balakrishnan MR, Heininger U, Menning L, Benes O, Pless R, Zuber PLF. Immunization stress-related response - redefining immunization anxiety-related reaction as an adverse event following immunization. Vaccine. 2020;38(14):3015–20., DOI: 10.1016/j.vaccine.2020.02.046 53 10.1016/j.vaccine.2020.02.046 false true Reference 27911747 /api/reference/27911747 54. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines. Ann Allergy Asthma Immunol. 2021;127(1):133–4., DOI: 10.1016/j.anai.2021.03.024 54 10.1016/j.anai.2021.03.024 false true Reference 27911748 /api/reference/27911748 55. Kelso JM. Covid-19: allergic-reactions-to-sars-cov-2-vaccines. https://www.uptodate.com/contents/covid-19-allergic-reactions-to-sars-cov-2-vaccines. Accessed 19 Dec 2021 55 false true Reference 27911749 /api/reference/27911749 56. Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, Su J, Shimabukuro TT, Shay DK. Anxiety-related adverse event clusters after Janssen COVID-19 vaccination - five U.S. mass vaccination sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(18):685–8., DOI: 10.15585/mmwr.mm7018e3 56 10.15585/mmwr.mm7018e3 false true Reference 27911750 /api/reference/27911750 57. Hoffman Y, Palgi Y, Goodwin R, Ben-Ezra M, Greenblatt-Kimron L. A storm in a teacup: older adults' low prevalence of COVID-19 vaccine side-effects and their link with vaccination anxiety. Int Psychogeriatr. 2021:1–3., DOI: 10.1017/S1041610221001071 57 10.1017/S1041610221001071 false true Reference 27911751 /api/reference/27911751 58. Hugli TE, Stimler NP, Gerard C, Moon KE. Possible role of serum anaphylatoxins in hypersensitivity reactions. Int Arch Allergy Appl Immunol. 1981;66(Suppl 1):113–20., DOI: 10.1159/000232882 58 10.1159/000232882 false true Reference 27911752 /api/reference/27911752 59. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol. 2017;140(2):335–48., DOI: 10.1016/j.jaci.2017.06.003 59 10.1016/j.jaci.2017.06.003 false true Reference 27911753 /api/reference/27911753 60. Lepow IH, Willms-Kretschmer K, Patrick RA, Rosen FS. Gross and ultrastructural observations on lesions produced by intradermal injection of human C3a in man. Am J Pathol. 1970;61(1):13–23. 60 false true Reference 27911754 /api/reference/27911754 61. Wuepper KD, Bokisch VA, Muller-Eberhard HJ, Stoughton RB. Cutaneous responses to human C 3 anaphylatoxin in man. Clin Exp Immunol. 1972;11(1):13–20. 61 false true Reference 27911755 /api/reference/27911755 62. Yancey KB, Hammer CH, Harvath L, Renfer L, Frank MM, Lawley TJ. Studies of human C5a as a mediator of inflammation in normal human skin. J Clin Invest. 1985;75(2):486–95., DOI: 10.1172/JCI111724 62 10.1172/JCI111724 false true Reference 27911756 /api/reference/27911756 63. Szebeni J, Stafil G, Fontana J, Dobbins D, Mongan P, Wassef N, Morse D, Bunger R, Alving C. Liposome-induced acute cardiopulmonary distress in swine is mediated by complement. Circulation. 1998;98(17):133–133. 63 false true Reference 27911757 /api/reference/27911757 64. Szebeni J. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement? Drug Discov Today. 2018;23(3):487–92., DOI: 10.1016/j.drudis.2018.01.025 64 10.1016/j.drudis.2018.01.025 false true Reference 27911758 /api/reference/27911758 65. Szebeni J, Bedőcs P, Dézsi L, Urbanics R. A porcine model of complement activation-related pseudoallergy to nano-pharmaceuticals: pros and cons of translation to a preclinical safety test. Prec Nanomed. 2018;1:63–73., DOI: 10.29016/180427.1 65 10.29016/180427.1 false true Reference 27911759 /api/reference/27911759 66. Alving CR. Natural antibodies against phospholipids and liposomes in humans. Biochem Soc Trans. 1984;12:342–4., DOI: 10.1042/bst0120342 66 10.1042/bst0120342 false true Reference 27911760 /api/reference/27911760 67. Swartz GM, Gentry MK, Amende LM, Blanchette-Mackie EJ, Alving CR. Antibodies to cholesterol. Proc Natl Acad Sci USA. 1988;85:1902–6., DOI: 10.1073/pnas.85.6.1902 67 10.1073/pnas.85.6.1902 false true Reference 27911761 /api/reference/27911761 68. Jiang H, Cooper B, Robey FA, Gewurz H. DNA binds and activates complement via residues 14–26 of the human C1q A chain. J Biol Chem. 1992;267(35):25597–601., DOI: 10.1016/S0021-9258(19)74082-4 68 10.1016/S0021-9258(19)74082-4 false true Reference 27911762 /api/reference/27911762 69. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol. 1991;146:4234–41. 69 false true Reference 27911763 /api/reference/27911763 70. Plank C, Mechtler K, Szoka FC Jr, Wagner E. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996;7:1437–46., DOI: 10.1089/hum.1996.7.12-1437 70 10.1089/hum.1996.7.12-1437 false true Reference 27911764 /api/reference/27911764 71. Ali YM, Ferrari M, Lynch NJ, Yaseen S, Dudler T, Gragerov S, Demopulos G, Heeney JL, Schwaeble WJ. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021;12:714511., DOI: 10.3389/fimmu.2021.714511 71 10.3389/fimmu.2021.714511 false true Reference 27911765 /api/reference/27911765 72. Selmin F, Musazzi UM, Franze S, Scarpa E, Rizzello L, Procacci P, Minghetti P. Pre-drawn syringes of Comirnaty for an efficient COVID-19 mass vaccination: demonstration of stability. Pharmaceutics. 2021;13(7):1029., DOI: 10.3390/pharmaceutics13071029 72 10.3390/pharmaceutics13071029 false true Reference 27911766 /api/reference/27911766 73. Nogueira S, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer MA, Blanchet CE, Svergun DI, Ramishetti S, Peer D, Langguth P, Sahin U, Haas H. Polysarcosine-Functionalized lipid nanoparticles for therapeutic mRNA delivery. ACS Appl Nano Mater. 2020;3(11):10634–45., DOI: 10.1021/acsanm.0c01834 73 10.1021/acsanm.0c01834 false true Reference 27911767 /api/reference/27911767 74. Sedic M, Senn JJ, Lynn A, Laska M, Smith M, Platz SJ, Bolen J, Hoge S, Bulychev A, Jacquinet E, Bartlett V, Smith PF. Safety evaluation of lipid nanoparticle-formulated modified mRNA in the Sprague-Dawley rat and cynomolgus monkey. Vet Pathol. 2018;55(2):341–54., DOI: 10.1177/0300985817738095 74 10.1177/0300985817738095 false true Reference 27911768 /api/reference/27911768 75. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH, Hruza GJ, Blumenthal KG, Fox LP, Freeman EE. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46–55., DOI: 10.1016/j.jaad.2021.03.092 75 10.1016/j.jaad.2021.03.092 false true Reference 27911769 /api/reference/27911769 76. Blumenthal KG, Freeman EE, Saff RR, Robinson LB, Wolfson AR, Foreman RK, Hashimoto D, Banerji A, Li L, Anvari S, Shenoy ES. Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2. N Engl J Med. 2021;384(13):1273–7., DOI: 10.1056/NEJMc2102131 76 10.1056/NEJMc2102131 false true Reference 27911770 /api/reference/27911770 77. Kolev M, Le Friec G, Kemper C. Complement–tapping into new sites and effector systems. Nat Rev Immunol. 2014;14(12):811–20., DOI: 10.1038/nri3761 77 10.1038/nri3761 false true Reference 27911771 /api/reference/27911771 78. Ozbakir B, Crielaard BJ, Metselaar JM, Storm G, Lammers T. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. J Control Release. 2014;190:624–36., DOI: 10.1016/j.jconrel.2014.05.039 78 10.1016/j.jconrel.2014.05.039 false true Reference 27911772 /api/reference/27911772 79. Wong AD, Ye M, Ulmschneider MB, Searson PC. Quantitative analysis of the enhanced permeation and retention (EPR) effect. PLoS One. 2015;10(5):e0123461., DOI: 10.1371/journal.pone.0123461 79 10.1371/journal.pone.0123461 false true Reference 27911773 /api/reference/27911773 80. Watanabe A, Tanaka H, Sakurai Y, Tange K, Nakai Y, Ohkawara T, Takeda H, Harashima H, Akita H. Effect of particle size on their accumulation in an inflammatory lesion in a dextran sulfate sodium (DSS)-induced colitis model. Int J Pharm. 2016;509(1–2):118–22., DOI: 10.1016/j.ijpharm.2016.05.043 80 10.1016/j.ijpharm.2016.05.043 false true Reference 27911774 /api/reference/27911774 81. Borg T, Gerdin B, Hallgren R, Warolin O, Modig J. Complement activation and its relationship to adult respiratory distress syndrome. An experimental study in pigs. Acta Anaesthesiol Scand. 1984;28(2):158–65., DOI: 10.1111/j.1399-6576.1984.tb02034.x 81 10.1111/j.1399-6576.1984.tb02034.x false true Reference 27911775 /api/reference/27911775 82. Marceau F, Lundberg C, Hugli TE. Effects of anaphylatoxins on circulation. Immunopharmacol. 1987;14:67–84., DOI: 10.1016/0162-3109(87)90031-2 82 10.1016/0162-3109(87)90031-2 false true Reference 27911776 /api/reference/27911776 83. Chanan-Khan A, Szebeni J, Leibes L, Rafique M, Savay S, Alving CR, Muggia FM. Complement activation by pegylated liposomal doxorubicin (DoxilR) in cancer patients: association with hypersensitivity reactions. J Control Drug Rel. 2001;abstract, in press. 83 false true Reference 27911777 /api/reference/27911777 84. Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100–8., DOI: 10.1038/s41565-018-0273-1 84 10.1038/s41565-018-0273-1 false true Reference 27911778 /api/reference/27911778 85. Meszaros T, Kozma GT, Shimizu T, Miyahara K, Turjeman K, Ishida T, Barenholz Y, Urbanics R, Szebeni J. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization. Int J Nanomedicine. 2018;13:6345–57., DOI: 10.2147/IJN.S161369 85 10.2147/IJN.S161369 false true Reference 27911779 /api/reference/27911779 86. Elsabahy M, Li A, Zhang F, Sultan D, Liu Y, Wooley KL. Differential immunotoxicities of poly(ethylene glycol)- vs. poly(carboxybetaine)-coated nanoparticles. J Control Release. 2013;172(3):641–52., DOI: 10.1016/j.jconrel.2013.09.010 86 10.1016/j.jconrel.2013.09.010 false true Reference 27911780 /api/reference/27911780 87. Elsabahy M, Wooley KL. Cytokines as biomarkers of nanoparticle immunotoxicity. Chem Soc Rev. 2013;42(12):5552–76., DOI: 10.1039/c3cs60064e 87 10.1039/c3cs60064e false true Reference 27911781 /api/reference/27911781 88. Chaplin H Jr. Review: the burgeoning history of the complement system 1888–2005. Immunohematology. 2005;21(3):85–93., DOI: 10.21307/immunohematology-2019-398 88 10.21307/immunohematology-2019-398 false true Reference 27911782 /api/reference/27911782 89. Bavli Y, Winkler I, Chen BM, Roffler S, Cohen R, Szebeni J, Barenholz Y. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs. J Control Release. 2019;306:138–48., DOI: 10.1016/j.jconrel.2019.06.007 89 10.1016/j.jconrel.2019.06.007 false true Reference 27911783 /api/reference/27911783 90. Kasperovic P. Dosages and methods for delivering lipid formulated nucleic acid molecules. US patent applicationsd #20160122759. 2016. 90 false true Reference 27911784 /api/reference/27911784 91. Fulop T, Kozma GT, Vashegyi I, Meszaros T, Rosivall L, Urbanics R, Storm G, Metselaar JM, Szebeni J. Liposome-induced hypersensitivity reactions: risk reduction by design of safe infusion protocols in pigs. J Control Release. 2019;309:333–8., DOI: 10.1016/j.jconrel.2019.07.005 91 10.1016/j.jconrel.2019.07.005 false true Reference 27911785 /api/reference/27911785 92. Klimek L, Novak N, Cabanillas B, Jutel M, Bousquet J, Akdis CA. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation. Allergy. 2021., DOI: 10.22541/au.160952242.21038379/v1 92 10.22541/au.160952242.21038379/v1 false true Reference 27911786 /api/reference/27911786 93. Murphy KR, Patel NC, Ein D, Hudelson M, Kodoth S, Marshall GD Jr, Parikh P, Blaiss MS. Insights from American College of Allergy, Asthma, and Immunology COVID-19 vaccine task force: allergic reactions to mRNA SARS-CoV-2 vaccines. Ann Allergy Asthma Immunol. 2021;126(4):319–20., DOI: 10.1016/j.anai.2021.01.017 93 10.1016/j.anai.2021.01.017 false true Reference 27911787 /api/reference/27911787 94. Kricorian K, Civen R, Equils O. COVID-19 vaccine hesitancy: misinformation and perceptions of vaccine safety. Hum Vaccin Immunother. 2021:1–8., DOI: 10.1080/21645515.2021.1950504 94 10.1080/21645515.2021.1950504 false true Reference 27911788 /api/reference/27911788 95. Ara Y, Saito T, Takagi T, Hagiwara E, Miyagi Y, Sugiyama M, Kawamoto S, Ishii N, Yoshida T, Hanashi D, Koshino T, Okada H, Okuda K. Zymosan enhances the immune response to DNA vaccine for human immunodeficiency virus type-1 through the activation of complement system. Immunology. 2001;103(1):98–105., DOI: 10.1046/j.1365-2567.2001.01201.x 95 10.1046/j.1365-2567.2001.01201.x false true Reference 27911789 /api/reference/27911789 96. Stager S, Alexander J, Kirby AC, Botto M, Rooijen NV, Smith DF, Brombacher F, Kaye PM. Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses. Nat Med. 2003;9(10):1287–92., DOI: 10.1038/nm933 96 10.1038/nm933 false true Reference 27911790 /api/reference/27911790 97. Mattsson J, Yrlid U, Stensson A, Schon K, Karlsson MC, Ravetch JV, Lycke NY. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. J Immunol. 2011;187(7):3641–52., DOI: 10.4049/jimmunol.1101107 97 10.4049/jimmunol.1101107 false true Reference 27911791 /api/reference/27911791 98. Hung CY, Hurtgen BJ, Bellecourt M, Sanderson SD, Morgan EL, Cole GT. An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection. Vaccine. 2012;30(31):4681–90., DOI: 10.1016/j.vaccine.2012.04.084 98 10.1016/j.vaccine.2012.04.084 false true Reference 27911792 /api/reference/27911792 99. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science. 1996;271(5247):348–50., DOI: 10.1126/science.271.5247.348 99 10.1126/science.271.5247.348 false true Reference 27911793 /api/reference/27911793 100. Morgan BP, Marchbank KJ, Longhi MP, Harris CL, Gallimore AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett. 2005;97(2):171–9., DOI: 10.1016/j.imlet.2004.11.010 100 10.1016/j.imlet.2004.11.010 false true /api/publication/32666145 Dézsi László et al. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor. (2022) GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) 2509-2715 2509-2723 44 2 597-618<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10005165"><a href="/gui2/?type=authors&mode=browse&sel=10005165" target="_blank">Dézsi László (<span class="authorship-author-name">Dézsi László</span> <span class="authorAux-mtmt"> Elméleti orvostudományok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10064003"><a href="/gui2/?type=authors&mode=browse&sel=10064003" target="_blank">Mészáros Tamás (<span class="authorship-author-name">Mészáros Tamás</span> <span class="authorAux-mtmt"> nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10024742"><a href="/gui2/?type=authors&mode=browse&sel=10024742" target="_blank">Kozma Gergely Tibor (<span class="authorship-author-name">Kozma Gergely Tibor</span> <span class="authorAux-mtmt"> Immunológia, Molekuláris biológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >H-Velkei Mária </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10075617"><a href="/gui2/?type=authors&mode=browse&sel=10075617" target="_blank">Oláh Csaba Zs. (<span class="authorship-author-name">Oláh Csaba Zsolt</span> <span class="authorAux-mtmt"> idegsebészet</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10092665"><a href="/gui2/?type=authors&mode=browse&sel=10092665" target="_blank">Szabó Miklós (<span class="authorship-author-name">Szabó Miklós</span> <span class="authorAux-mtmt"> tüdőgyógyászat, klinikai onkológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10032791"><a href="/gui2/?type=authors&mode=browse&sel=10032791" target="_blank">Patkó Zsófia (<span class="authorship-author-name">Patkó Zsófia Panna</span> <span class="authorAux-mtmt"> farmakokinetika, nukleáris medicina, radiológia</span>) </a> </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10053120"><a href="/gui2/?type=authors&mode=browse&sel=10053120" target="_blank">Fülöp Tamás (<span class="authorship-author-name">Fülöp Tamás</span> <span class="authorAux-mtmt"> Liposzomális nanomedicina vizsgálatok</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Hennies Mark </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Szebeni Miklós </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10072454"><a href="/gui2/?type=authors&mode=browse&sel=10072454" target="_blank">Barta Bálint András (<span class="authorship-author-name">Barta Bálint András</span> <span class="authorAux-mtmt"> Experimentális kardiológia, Proteomika</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Városmajori Szív- és Érgyógyászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10002691"><a href="/gui2/?type=authors&mode=browse&sel=10002691" target="_blank">Merkely Béla (<span class="authorship-author-name">Merkely Béla Péter</span> <span class="authorAux-mtmt"> Kardiológia</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Városmajori Szív- és Érgyógyászati Klinika; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/<span title="Városmajori Szív- és Érgyógyászati Klinika">VAROSMAJOR_SZÍVÉRGYÓGY</span>/Sportorvostan Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10013969"><a href="/gui2/?type=authors&mode=browse&sel=10013969" target="_blank">Radovits Tamás^** (<span class="authorship-author-name">Radovits Tamás</span> <span class="authorAux-mtmt"> kardiológia, érgyógyászat</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Városmajori Szív- és Érgyógyászati Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003266"><a href="/gui2/?type=authors&mode=browse&sel=10003266" target="_blank">Szebeni János ✉ (<span class="authorship-author-name">Szebeni János</span> <span class="authorAux-mtmt"> Klinikai orvostudomány, immunológia, nanomedicina</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/<span title="Transzlációs Medicina Intézet">TMI</span>/Nanomedicina Kutató és Oktató Központ; <span title="Miskolci Egyetem">ME</span>/<span title="Egészségtudományi Kar ">ETK</span>/Elméleti Egészségtudományok Intézete; <span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Intézet">I</span>/Transzlációs Medicina Intézet</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32666145" target="_blank">A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor</a></div> <div> <span class="journal-title">GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE)</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2715">2509-2715</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/2509-2723">2509-2723</a>)</span>: <span class="journal-volume">44</span> <span class="journal-issue">2</span> <span class="page"> pp 597-618 </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GREEN" title=" Green "> <a style="color:blue" title="10.1007/s11357-021-00495-y" target="_blank" href="https://doi.org/10.1007/s11357-021-00495-y"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000753709600001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000753709600001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85124573206" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124573206"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="35146583" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35146583&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Complementary and Alternative Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Veterinary (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;D1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Aging&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Cardiology and Cardiovascular Medicine&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Geriatrics and Gerontology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 51</span> | Független: 37 | Függő: 14 | Nem jelölt: 0 | WoS jelölt: 42 | Scopus jelölt:&nbsp;37 | WoS/Scopus jelölt:&nbsp;45 | DOI jelölt:&nbsp;46 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32666145&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 20 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32666145</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="funder"> (Open access funding of Semmelweis University), European Union Horizon 2020 projects(825828), European Union Horizon 2020 projects(952520), (2020-1.1.6-JOVO-2021-00013) </div> <div class="lastModified">Utolsó módosítás: 2026.09.03. 10:26 Milánkovics Róbert (PTE ÁOK admin 4) </div> <pre class="comment" style="margin-top: 0; margin-bottom: 0;"><u>Megjegyzés</u>: Tamás Radovits and János Szebeni contributed equally to the article.</pre> </div></div>